Interactions with rilpivirine and comedications are now available on the website and the HIV iCharts app. The printable versions of the charts and HIV-Charts2Go have also been updated to include these new interactions.
Rilpivirine is primarily metabolized by cytochrome P450 (CYP)3A - drugs that induce or inhibit CYP3A may affect the clearance of rilpivirine. At the recommended dose of 25 mg once daily, rilpivirine is not likely to have a clinically relevant effect on the exposure of medicinal products metabolised by CYP enzymes.
Rilpivirine is primarily metabolized by cytochrome P450 (CYP)3A - drugs that induce or inhibit CYP3A may affect the clearance of rilpivirine. At the recommended dose of 25 mg once daily, rilpivirine is not likely to have a clinically relevant effect on the exposure of medicinal products metabolised by CYP enzymes.
Rilipivirine was licensed a few months ago by the FDA in the US and has been recommended for approval in Europe by the EMA. Rilpivirine is marketed as Edurant® and is also available in as a coformulation (Complera®, Eviplera®) with emtricitabine and tenofovir.
